jamesi 50 mg/1000 mg apvalkotās tabletes
zentiva, k.s., czech republic - sitagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/1000 mg
sitagliptin/metformin grindeks 50 mg/850 mg apvalkotās tabletes
grindeks, as, latvia - sitagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/850 mg
sitagliptin/metformin grindeks 50 mg/1000 mg apvalkotās tabletes
grindeks, as, latvia - sitagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/1000 mg
metformin zentiva 500 mg apvalkotās tabletes
zentiva, k.s., czech republic - metformīna hidrohlorīds - apvalkotā tablete - 500 mg
metformin zentiva 850 mg apvalkotās tabletes
zentiva, k.s., czech republic - metformīna hidrohlorīds - apvalkotā tablete - 850 mg
metformin zentiva 1000 mg apvalkotās tabletes
zentiva, k.s., czech republic - metformīna hidrohlorīds - apvalkotā tablete - 1000 mg
sitagliptin/metformin hydrochloride teva 50 mg/850 mg apvalkotās tabletes
teva gmbh, germany - sitagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/850 mg
sitagliptin/metformin hydrochloride teva 50 mg/1000 mg apvalkotās tabletes
teva gmbh, germany - sitagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/1000 mg
sitagliptin / metformin hydrochloride mylan
mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - cukura diabēts, 2. tips - cukura diabēts - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , triple kombinēto terapiju), kā palīglīdzekli, lai diētu un vingrošanu pacientiem nepietiekami kontrolē par to maksimālā pieļaujama devu metformīns un sulfonilurīnvielas pamata. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
sitagliptin/metformin hydrochloride sandoz 50 mg/850 mg apvalkotās tabletes
sandoz d.d., slovenia - sitagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/850 mg